Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kraslavas Aprinkis, Latvia Clinical Trials

A listing of Kraslavas Aprinkis, Latvia clinical trials actively recruiting patients volunteers.


Found (2201) clinical trials

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Chronic exertional compartment syndrome (CECS) is an overuse injury first described by Mavor in 1956 that typically affects young endurance athletes, classically distance runners. CECS occurs primarily in the lower leg, predominantly in the anterior compartment, although it has been reported elsewhere in the body. The pathophysiology of CECS is …


A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.


A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma

This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A in adults with r/r MM. Before initiating the study treatment PBCAR269A, all study participants will be administered lymphodepletion chemotherapy. The initial lymphodepletion chemotherapy regimen will be composed of …


A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts: EXP-1: ROS1 TKI-nave ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of …


Safety Pharmacokinetics (PK) and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

After screening, participants are assigned to either the Dose Escalation Phase or Dose Confirmation Phase. The Dose Escalation Phase consists of 3 cohorts and will evaluate available PK and safety data from the first 6 participants of each cohort, including dose limiting toxicities (DLTs). The purpose of the Dose Confirmation …


Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is an open label safety and efficacy evaluation with comparison of toxicity to a historical control population (TOTXVI).There will be 3 cohorts of patients enrolled, and the dose for each cohort will be determined based on the toxicities experienced in the ongoing and prior cohorts. An initial 9 patients …


A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study to establish the recommended phase 2 dose (RP2D) for erdafitinib and cetrelimab and/or platinum (cisplatin or carboplatin) chemotherapy, and the safety of erdafitinib in …


Gene Transfer Study in Patients With Late Onset Pompe Disease

This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion. Up to 2 nominal dose levels of AT845 are planned to be evaluated in FORTIS. A …


Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly. There is no treatment for geographic atrophy (GA), the advanced stage of dry AMD, in which cells of the neurosensory retina and associated retinal pigment epithelium (RPE) gradually degenerate and die. Advances in stem cell biology …


Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Background We generated a chimeric antigen receptor (CAR) that engages CD70 using its natural ligand CD27, as the binding moiety. Transducing peripheral blood lymphocytes (PBL) with this CAR conveys major histocompatibility complex (MHC)-independent recognition of CD70-expressing target cells, which include renal cell carcinoma and other cancers. In co-cultures with CD70+ …